Celgene International Sárl Release: ABRAXANE® Plus Gemcitabine Receives European Marketing Authorization For First-Line Treatment Of Patients With Metastatic Pancreatic Cancer
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.1
Help employers find you! Check out all the jobs and post your resume.